Document Type
Honors Thesis
Abstract
A local delivery method of an injectable modified cellulose nanofiber hydrogel, DNCNF PAA 10%, loaded with the chemotherapy drug temozolomide, TMZ, was studied to investigate the most effective and safest therapy window on duke melanoma 6 (DM6) and human dermal fibroblast cells (HDF-α). Loaded hydrogel concentrations of 25μM1000μM were administered inside PDMS microcurrent device for 72 hours, removed, cells stained, and quantified. For the long-term study, treatment was administered for 72 hours, treatment removed, and cells recovered for 72 hours. The data was quantified using a fluorescent live/dead cell assay and cells counted. There was a cell death dosage effect seen after the 250μM TMZ hydrogel treatment as the concentrations increased. The 500μM TMZ hydrogel had ~7-14% DM6 viability with ~50% HDF-α viability. Dosages higher than the 500μM TMZ hydrogel treatment and free 500μM TMZ had nonspecific killing of both cell types. The long-term melanoma recovery study showed surviving melanoma have possible TMZ resistance. The most effective and safest therapy window was DNCNF PAA 10% 500μM-750μM TMZ. Currently, the treatment therapy window found is being studied further involving co-culturing of both cell types. Future studies recommended are TMZ resistance studies and in vivo animal studies.
Publication Date
5-1-2023
Language
English
License
This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 International License.
Recommended Citation
Meyers, Kayla, "MELANOMA CHEMOTHERAPY TREATMENT USING MODIFIED CELLULOSE-BASED INJECTABLE HYDROGEL COMBINED WITH TEMOZOLOMIDE" (2023). 2023 Spring Honors Capstone Projects. 46.
https://mavmatrix.uta.edu/honors_spring2023/46